CN117651703A - 取代的氨基甲酸大环化合物及其相关治疗方法 - Google Patents

取代的氨基甲酸大环化合物及其相关治疗方法 Download PDF

Info

Publication number
CN117651703A
CN117651703A CN202280047652.3A CN202280047652A CN117651703A CN 117651703 A CN117651703 A CN 117651703A CN 202280047652 A CN202280047652 A CN 202280047652A CN 117651703 A CN117651703 A CN 117651703A
Authority
CN
China
Prior art keywords
alkylene
alkyl
cycloalkyl
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280047652.3A
Other languages
English (en)
Chinese (zh)
Inventor
L·D·彭宁顿
崔永吉
黄霍安
B·M·阿奎拉
I·A·马格
胡元
J·R·伍兹
B·K·雷默
J·M·本齐恩
J·W·莱曼
M·R·哈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of CN117651703A publication Critical patent/CN117651703A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280047652.3A 2021-05-26 2022-05-25 取代的氨基甲酸大环化合物及其相关治疗方法 Pending CN117651703A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193256P 2021-05-26 2021-05-26
US63/193,256 2021-05-26
PCT/US2022/030841 WO2022251304A1 (en) 2021-05-26 2022-05-25 Substituted carbamate macrocyclic compounds and related methods of treatment

Publications (1)

Publication Number Publication Date
CN117651703A true CN117651703A (zh) 2024-03-05

Family

ID=82156598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280047652.3A Pending CN117651703A (zh) 2021-05-26 2022-05-25 取代的氨基甲酸大环化合物及其相关治疗方法

Country Status (8)

Country Link
US (1) US20240174689A1 (https=)
EP (1) EP4347604B1 (https=)
JP (1) JP7833486B2 (https=)
CN (1) CN117651703A (https=)
AU (1) AU2022280804A1 (https=)
CA (1) CA3219490A1 (https=)
ES (1) ES3057101T3 (https=)
WO (1) WO2022251304A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111051295A (zh) * 2017-08-03 2020-04-21 武田药品工业株式会社 杂环化合物及其用途
WO2020167701A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
PE20161064A1 (es) 2013-12-12 2016-10-28 Univ Tsukuba Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
PL3411358T3 (pl) 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) * 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111051295A (zh) * 2017-08-03 2020-04-21 武田药品工业株式会社 杂环化合物及其用途
WO2020167701A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
EP4347604B1 (en) 2025-12-03
JP7833486B2 (ja) 2026-03-19
JP2024520396A (ja) 2024-05-24
WO2022251304A1 (en) 2022-12-01
EP4347604C0 (en) 2025-12-03
ES3057101T3 (en) 2026-02-26
AU2022280804A1 (en) 2023-11-30
CA3219490A1 (en) 2022-12-01
US20240174689A1 (en) 2024-05-30
WO2022251304A8 (en) 2023-01-05
EP4347604A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7465945B2 (ja) Ｂｅｔ阻害剤としてのヘテロ環式化合物
CN117440955A (zh) 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物
JP7017521B2 (ja) アクチビン受容体様キナーゼの阻害剤
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
DE60315615T2 (de) Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
AU2021306755B2 (en) Immunomodulator
CN117999265A (zh) 取代的融合双环大环化合物及其相关治疗方法
CN117651703A (zh) 取代的氨基甲酸大环化合物及其相关治疗方法
JP5204227B2 (ja) ベンゼンスルホニル−クロマン、チオクロマン、テトラヒドロナフタレン、および関連するガンマセクレターゼインヒビター
EP3929185A1 (en) Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof
JP2020507606A (ja) カルシウムチャネル阻害剤
CA3145344A1 (en) Pyrazolopyrimidine compound, preparation method for same and applications thereof
CN119730843A (zh) 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
CN119768169A (zh) 取代的稠合二环化合物以及相关的治疗方法
CN119730848A (zh) 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
WO2026078558A1 (en) Compounds active on cyclin d1 pathway and their use
EA048322B1 (ru) Гетероциклические соединения в качестве ингибиторов bet

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination